found that stage II and III breast cancers bearing a PIK3CA mutation, treated in a neoadjuvant setting with standard chemotherapy were associated with lower rates of pathological complete response (pCR), which could reflect chemoresistance in these tumors12. This evidence concerns the gene PIK3CA and breast carcinoma.